WO2009007675A2 - Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires - Google Patents
Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires Download PDFInfo
- Publication number
- WO2009007675A2 WO2009007675A2 PCT/GB2008/002201 GB2008002201W WO2009007675A2 WO 2009007675 A2 WO2009007675 A2 WO 2009007675A2 GB 2008002201 W GB2008002201 W GB 2008002201W WO 2009007675 A2 WO2009007675 A2 WO 2009007675A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mast cell
- pharmaceutically
- antagonist
- kit
- cell inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
L'invention porte sur des produits d'association comprenant (a) un inhibiteur de mastocyte, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci; et (b) un antagoniste P2Y12, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci. De tels produits d'association ont une utilité particulière dans le traitement de l'athérosclérose et d'états apparentés.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92972907P | 2007-07-11 | 2007-07-11 | |
US92973207P | 2007-07-11 | 2007-07-11 | |
US60/929,729 | 2007-07-11 | ||
US60/929,732 | 2007-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009007675A2 true WO2009007675A2 (fr) | 2009-01-15 |
WO2009007675A3 WO2009007675A3 (fr) | 2009-03-12 |
Family
ID=39769186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002201 WO2009007675A2 (fr) | 2007-07-11 | 2008-06-25 | Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009007675A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2229172A1 (fr) * | 2007-12-03 | 2010-09-22 | AstraZeneca AB | Composés de triazolo [4,5-d] pyrimidine pour le traitement d'anévrysmes aortiques abdominaux |
WO2010139985A1 (fr) * | 2009-06-01 | 2010-12-09 | Biocopea Limited | Utilisation de l'amlexanoxe comme thérapie des maladies induites par les neutrophiles |
EP2377520A1 (fr) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Composition pharmaceutique du prasugrel |
EP2505196A1 (fr) * | 2009-11-27 | 2012-10-03 | Tokai University Educational System | Agent antithrombotique |
US8663661B2 (en) * | 2009-12-23 | 2014-03-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
WO2017125739A1 (fr) * | 2016-01-21 | 2017-07-27 | Rspr Pharma Ab | Nouvelle utilisation de pémirolast |
CN109646442A (zh) * | 2019-01-29 | 2019-04-19 | 军事科学院军事医学研究院生物医学分析中心 | 乙酸酯类化合物在制备环鸟腺苷合成酶乙酰化药物中的用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
EP0316174A1 (fr) * | 1987-11-10 | 1989-05-17 | Tokyo Tanabe Company Limited | Préparation aqueuse du sel de potassium du 9-méthyle-3-(1H-tétrazol-5-yle)-4H-pyrido[1,2-a]-pyrimidine-4-one |
EP0766963A1 (fr) * | 1994-05-31 | 1997-04-09 | Tokyo Tanabe Company Limited | Depresseur de l'arteriosclerose |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
EP1285921A1 (fr) * | 2001-08-10 | 2003-02-26 | Dinamite Dipharma S.p.A. | Procédé de la fabrication de pemirolast pure |
US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
US20050181023A1 (en) * | 2004-02-17 | 2005-08-18 | Young Janel E. | Drug-enhanced adhesion prevention |
WO2005092264A1 (fr) * | 2004-03-10 | 2005-10-06 | Ethicon, Inc. | Prevention des adherences amelioree par des medicaments |
WO2007024472A2 (fr) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | Procede pour le traitement de maladies vasculaires |
-
2008
- 2008-06-25 WO PCT/GB2008/002201 patent/WO2009007675A2/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086349A (en) * | 1975-07-30 | 1978-04-25 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma |
US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
EP0316174A1 (fr) * | 1987-11-10 | 1989-05-17 | Tokyo Tanabe Company Limited | Préparation aqueuse du sel de potassium du 9-méthyle-3-(1H-tétrazol-5-yle)-4H-pyrido[1,2-a]-pyrimidine-4-one |
EP0766963A1 (fr) * | 1994-05-31 | 1997-04-09 | Tokyo Tanabe Company Limited | Depresseur de l'arteriosclerose |
US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
US20020103219A1 (en) * | 2000-10-05 | 2002-08-01 | Jeremy Jacob | Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders |
EP1285921A1 (fr) * | 2001-08-10 | 2003-02-26 | Dinamite Dipharma S.p.A. | Procédé de la fabrication de pemirolast pure |
US20050181023A1 (en) * | 2004-02-17 | 2005-08-18 | Young Janel E. | Drug-enhanced adhesion prevention |
WO2005092264A1 (fr) * | 2004-03-10 | 2005-10-06 | Ethicon, Inc. | Prevention des adherences amelioree par des medicaments |
WO2007024472A2 (fr) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | Procede pour le traitement de maladies vasculaires |
Non-Patent Citations (17)
Title |
---|
"PEMIROLAST POTASSIUM" DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 28, no. 1, 1 January 1992 (1992-01-01), pages 29-31, XP008066535 ISSN: 0025-7656 * |
ISAJI M ET AL: "TRANILAST INHIBITS THE PROLIFERATION, CHEMOTAXIS AND TUBE FORMATIONOF HUMAN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO AND ANGIOGENESIS IN VIVO" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 122, no. 6, November 1997 (1997-11), pages 1061-1066, XP000997892 ISSN: 0007-1188 * |
JONES N L ET AL: "Ketotifen therapy for acute ulcerative colitis in children: A pilot study" DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 3, March 1998 (1998-03), pages 609-615, XP008086243 ISSN: 0163-2116 * |
MARSHALL J K ET AL: "Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance" CANADIAN JOURNAL OF GASTROENTEROLOGY, MEDICARE PUBL., OAKVILLE, CA, vol. 12, no. 4, 1998, pages 273-275, XP008086245 ISSN: 0835-7900 * |
MATSUMURA ET AL: "Suppression of atherosclerotic development in watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast" MEDLINE, 23 February 1999 (1999-02-23), XP002953929 * |
MINOCHA A ET AL: "Role of ketotifen in pathogenesis of chronic ulcerative colitis" GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 104, no. 4 SUPPL, 1993, page A746, XP008086242 ISSN: 0016-5085 * |
NOBUHIDE O ET AL: "Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease" GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 56, no. 4, April 2007 (2007-04), pages 599-600, XP008086231 ISSN: 0017-5749 * |
SAIURA A ET AL: "Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 433, no. 2-3, 21 December 2001 (2001-12-21), pages 163-168, XP008086230 ISSN: 0014-2999 * |
SHIMIZU T ET AL: "INHIBITORY EFFECTS OF AZELASTINE AND TRANILAST ON LEUKOTRIENE B4 AND LEUKOTRIENE C4, GENERATION BY RAT COLONIC MUCOSA" PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 53, no. 5, 1995, pages 355-358, XP001042184 ISSN: 0952-3278 * |
STILLER-MATULA J ET AL: "Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance" THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 97, no. 3, March 2007 (2007-03), pages 385-393, XP008086107 ISSN: 0340-6245 * |
SUWAKI T ET AL: "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug" INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 12, November 2001 (2001-11), pages 2163-2171, XP002443957 ISSN: 1567-5769 * |
TAMAOKI JUN: "Role of a Th2 cytokine inhibitor in asthma treatment" ALLERGOLOGY INTERNATIONAL, BLACKWELL SCIENCE, CARLTON,, AU, vol. 53, no. 2, June 2004 (2004-06), pages 55-60, XP002443956 ISSN: 1323-8930 * |
TEH L G ET AL: "Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis?" BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 17, no. 2, 1984, pages 157-159, XP008086082 ISSN: 0306-5251 * |
WALLENTIN L C ET AL: "Prasugrel (CS-747), a novel thienopyridine P2Y12 receptor antagonist, results in more effective platelet inhibition than clopidogrel in aspirin-treated patients with atherosclerotic disease" EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 26, no. Suppl1, 6 September 2005 (2005-09-06), page 488, XP008086116 ISSN: 0195-668X * |
YAMADA N ET AL: "MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 6, 25 September 1992 (1992-09-25), pages 1211-1213, XP023732179 ISSN: 0006-2952 [retrieved on 1992-09-25] * |
YANAGIHARA Y ET AL: "Immunopharmacological studies on TBX, a new antiallergic drug. (4) Effects on type II to IV allergic reactions and immunological functions in animal models" JAPANESE JOURNAL OF PHARMACOLOGY, JPTHE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, vol. 51, no. 1, 1 January 1989 (1989-01-01), pages 93-100, XP008066536 ISSN: 0021-5198 * |
ZHANG W ET AL: "Development of new therapeutic effect and mechanism of tranilast" ZHONGGUO XIN YAO YU LINCHUANG ZAZHI - CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, SHANGHAI SHI YIYAO GUANLIJU KE-JI QINGBAO YANJIUSUO ZHONGGUO, CN, vol. 23, no. 11, November 2004 (2004-11), pages 795-798, XP008086232 ISSN: 1007-7669 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2229172A1 (fr) * | 2007-12-03 | 2010-09-22 | AstraZeneca AB | Composés de triazolo [4,5-d] pyrimidine pour le traitement d'anévrysmes aortiques abdominaux |
EP2229172A4 (fr) * | 2007-12-03 | 2012-12-26 | Astrazeneca Ab | Composés de triazolo [4,5-d] pyrimidine pour le traitement d'anévrysmes aortiques abdominaux |
WO2010139985A1 (fr) * | 2009-06-01 | 2010-12-09 | Biocopea Limited | Utilisation de l'amlexanoxe comme thérapie des maladies induites par les neutrophiles |
JP2012528844A (ja) * | 2009-06-01 | 2012-11-15 | バイオコピア リミテッド | 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用 |
EP2505196A1 (fr) * | 2009-11-27 | 2012-10-03 | Tokai University Educational System | Agent antithrombotique |
EP2505196A4 (fr) * | 2009-11-27 | 2013-05-01 | Univ Tokai Educational System | Agent antithrombotique |
US8663661B2 (en) * | 2009-12-23 | 2014-03-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
US20140147505A1 (en) * | 2009-12-23 | 2014-05-29 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
EP2377520A1 (fr) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Composition pharmaceutique du prasugrel |
WO2017125739A1 (fr) * | 2016-01-21 | 2017-07-27 | Rspr Pharma Ab | Nouvelle utilisation de pémirolast |
CN109646442A (zh) * | 2019-01-29 | 2019-04-19 | 军事科学院军事医学研究院生物医学分析中心 | 乙酸酯类化合物在制备环鸟腺苷合成酶乙酰化药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2009007675A3 (fr) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100184783A1 (en) | Combination for use in the treatment of inflammatory atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist | |
WO2009007675A2 (fr) | Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires | |
EP2120919B1 (fr) | Nouvelle association destinée à être utilisée dans le traitement de troubles inflammatoires | |
WO2009007674A2 (fr) | Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires | |
WO2009007679A2 (fr) | Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires | |
EP2303251B1 (fr) | Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires | |
EP2107907B1 (fr) | Combinaison de pémirolast et ramatrobane pour l'utilisation dans le traitement de troubles inflammatoires | |
EP2129368B1 (fr) | Combinaison pour l'utilisation dans le traitement des inflammations | |
WO2009122182A1 (fr) | Nouvelle combinaison destinée au traitement de troubles inflammatoires | |
WO2009122183A1 (fr) | Nouvelle combinaison destinée au traitement de troubles inflammatoires | |
WO2009122181A1 (fr) | Nouvelle combinaison destinée au traitement de troubles inflammatoires | |
WO2009007680A2 (fr) | Nouvelle combinaison destinée à être utilisée dans le traitement de troubles inflammatoires | |
US20100099693A1 (en) | New combination for use in the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762504 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08762504 Country of ref document: EP Kind code of ref document: A2 |